[Current treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia in the TKI era].
作者信息
Shen Y J, Zhu H H
机构信息
The Department of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou 310003, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2020 Sep 14;41(9):779-782. doi: 10.3760/cma.j.issn.0253-2727.2020.09.017.
Abstract
摘要
相似文献
1
[Current treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia in the TKI era].
Zhonghua Xue Ye Xue Za Zhi. 2020 Sep 14;41(9):779-782. doi: 10.3760/cma.j.issn.0253-2727.2020.09.017.
2
Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
Cancer Med. 2021 Dec;10(24):8741-8753. doi: 10.1002/cam4.4413. Epub 2021 Nov 11.
3
[Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].
Rinsho Ketsueki. 2020;61(9):1227-1235. doi: 10.11406/rinketsu.61.1227.
4
Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ Program. 2011;2011:231-7. doi: 10.1182/asheducation-2011.1.231.
5
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Acta Haematol. 2021;144(3):285-292. doi: 10.1159/000510112. Epub 2020 Nov 25.
6
Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors.
Chemotherapy. 2019;64(2):81-93. doi: 10.1159/000501061. Epub 2019 Aug 7.
7
Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Cancer. 2023 May 15;129(10):1523-1536. doi: 10.1002/cncr.34710. Epub 2023 Mar 7.
8
The Impact of Post-Hematopoietic Stem Cell Transplant Tyrosine Kinase Inhibitors in Philadelphia-Positive Acute Lymphoblastic Leukemia.
Hematol Oncol Stem Cell Ther. 2022 Dec 23;15(4):219-222. doi: 10.1016/j.hemonc.2021.07.003.
9
The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Clin Adv Hematol Oncol. 2023 Feb;21(2):68-75.
10
Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Cancer. 2016 Oct;122(19):2941-51. doi: 10.1002/cncr.30130. Epub 2016 Jun 16.
本文引用的文献
1
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Am J Hematol. 2019 Dec;94(12):1388-1395. doi: 10.1002/ajh.25648. Epub 2019 Oct 21.
2
Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation.
Leuk Lymphoma. 2020 Feb;61(2):429-436. doi: 10.1080/10428194.2019.1663417. Epub 2019 Sep 12.
3
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Curr Treat Options Oncol. 2019 Jan 24;20(1):4. doi: 10.1007/s11864-019-0603-z.
4
Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
Leukemia. 2019 Jun;33(6):1313-1323. doi: 10.1038/s41375-018-0315-6. Epub 2018 Dec 13.
5
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.
6
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Ann Hematol. 2018 Sep;97(9):1535-1545. doi: 10.1007/s00277-018-3323-8. Epub 2018 Apr 24.
7
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):257-265. doi: 10.1016/j.clml.2018.02.010. Epub 2018 Feb 17.
8
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
9
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925.
10
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant. 2018 Apr;24(4):741-750. doi: 10.1016/j.bbmt.2017.12.777. Epub 2017 Dec 13.
Zotero 插件